Sol-Gel Technologies Ltd. Overview
Pro stress-test →Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's proprietary silica-based microencapsulation technology platform enables drug substances to be entrapped in porous silica microcapsules to address limitations of topical drug delivery by stabilizing active drug ingredients, extending drug delivery time and reducing potential irritation caused by direct application to the skin.
Strategic Profile
Pro stress-test →Sol-Gel markets two approved products: Twyneo (once-daily topical cream for acne vulgaris) and Epsolay (once-daily topical cream for papulopustular rosacea). The clinical pipeline includes SGT-610 in Phase 3 trials for Gorlin Syndrome and SGT-210 (which completed Phase I clinical trial) for rare hyperkeratinization disorders. In March 2026, the company completed an oversubscribed offering of 459,112 shares at $72.00 per share, generating $33.1 million in gross proceeds to fund continued development of SGT-610 and R&D activities.
Competitive Landscape
Pro stress-test →Sol-Gel competes in a fragmented topical dermatology market dominated by larger pharmaceutical companies and specialty dermatology firms. Key competitors include Galderma (products like MetroLotion and Doxycycline hyclate for rosacea), Bausch + Lomb (Zoistat, topical treatments), and various generic manufacturers. The company's differentiation relies on its proprietary silica microencapsulation technology platform and focus on rare and common skin conditions across its branded and generic portfolios.
Industry Context
Sol-Gel Technologies Ltd. operates in Topical dermatology pharmaceuticals.
Key facts
Founded: N/A · Headquarters: Ness Ziona, Israel · Employees: N/A · Revenue: $0.1M (Q1 2026) · Market cap: N/A